Cargando…
1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)
BACKGROUND: Polymyxins are important antimicrobial agents for the treatment of infections due to carbapenem-resistant and other multidrug-resistant organisms. Recently, the CLSI and EUCAST have set breakpoints for colistin (EUCAST and CLSI) and polymyxin B (CLSI) with slight differences in recommend...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809955/ http://dx.doi.org/10.1093/ofid/ofz360.1398 |
_version_ | 1783462127039676416 |
---|---|
author | Pogue, Jason M Jones, Ronald N Bradley, John S Andes, David Bhavnani, Sujata M Dudley, Michael Flamm, Robert K Rodvold, Keith A Ambrose, Paul G |
author_facet | Pogue, Jason M Jones, Ronald N Bradley, John S Andes, David Bhavnani, Sujata M Dudley, Michael Flamm, Robert K Rodvold, Keith A Ambrose, Paul G |
author_sort | Pogue, Jason M |
collection | PubMed |
description | BACKGROUND: Polymyxins are important antimicrobial agents for the treatment of infections due to carbapenem-resistant and other multidrug-resistant organisms. Recently, the CLSI and EUCAST have set breakpoints for colistin (EUCAST and CLSI) and polymyxin B (CLSI) with slight differences in recommendations. However, there are issues unique to the polymyxin class that warrant additional guidances. Herein, we assess data related to breakpoint setting and make additional recommendations for polymyxin AST interpretive criteria. METHODS: Data sources included longitudinal (2011–2017) US surveillance reference broth microdilution (BMD) MIC distributions (128,573 isolates) for colistin and polymyxin B (PB), published data on accuracy of various AST methodologies, in vivo pharmacokinetic/pharmacodynamic (PK-PD) models, prior polymyxin guidelines and agency package insert dosing recommendations, and population PK-PD and toxicodynamic (TD) data. Epidemiological cut-off, PK-PD (and TD), and clinical data were all considered for susceptible (S) breakpoint determinations. RESULTS: Data demonstrate that the most commonly utilized AST methodologies (disk diffusion, Etest, and automated MIC susceptibility panels), as well as agar dilution testing cannot reliably detect resistance; and BMD is the preferred AST. Importantly, colistin S is a reliable surrogate for PB S with cross-S accuracy at > 99% of isolates in each pathogen group. Breakpoint recommendations can be found in the Table with emphasis on applying combination therapy. Key recommendations include an S breakpoint of ≤2 mg/L for each pathogen (both colistin and PB). However, based on a lack of preclinical efficacy in murine pneumonia models, PK/PD concerns, and poor clinical outcome data, we strongly suggest that no breakpoints are applied for pneumonia and that alternative therapies should be used where available. Additionally, due to a lack of significant renal excretion, PB will also have no S breakpoint recommendation for lower urinary tract infections. CONCLUSION: The polymyxins have compromising characteristics that make them suboptimal antimicrobials when used alone, and additional caveats are required for AST breakpoint interpretive criteria and stewardship programs. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6809955 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68099552019-10-28 1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) Pogue, Jason M Jones, Ronald N Bradley, John S Andes, David Bhavnani, Sujata M Dudley, Michael Flamm, Robert K Rodvold, Keith A Ambrose, Paul G Open Forum Infect Dis Abstracts BACKGROUND: Polymyxins are important antimicrobial agents for the treatment of infections due to carbapenem-resistant and other multidrug-resistant organisms. Recently, the CLSI and EUCAST have set breakpoints for colistin (EUCAST and CLSI) and polymyxin B (CLSI) with slight differences in recommendations. However, there are issues unique to the polymyxin class that warrant additional guidances. Herein, we assess data related to breakpoint setting and make additional recommendations for polymyxin AST interpretive criteria. METHODS: Data sources included longitudinal (2011–2017) US surveillance reference broth microdilution (BMD) MIC distributions (128,573 isolates) for colistin and polymyxin B (PB), published data on accuracy of various AST methodologies, in vivo pharmacokinetic/pharmacodynamic (PK-PD) models, prior polymyxin guidelines and agency package insert dosing recommendations, and population PK-PD and toxicodynamic (TD) data. Epidemiological cut-off, PK-PD (and TD), and clinical data were all considered for susceptible (S) breakpoint determinations. RESULTS: Data demonstrate that the most commonly utilized AST methodologies (disk diffusion, Etest, and automated MIC susceptibility panels), as well as agar dilution testing cannot reliably detect resistance; and BMD is the preferred AST. Importantly, colistin S is a reliable surrogate for PB S with cross-S accuracy at > 99% of isolates in each pathogen group. Breakpoint recommendations can be found in the Table with emphasis on applying combination therapy. Key recommendations include an S breakpoint of ≤2 mg/L for each pathogen (both colistin and PB). However, based on a lack of preclinical efficacy in murine pneumonia models, PK/PD concerns, and poor clinical outcome data, we strongly suggest that no breakpoints are applied for pneumonia and that alternative therapies should be used where available. Additionally, due to a lack of significant renal excretion, PB will also have no S breakpoint recommendation for lower urinary tract infections. CONCLUSION: The polymyxins have compromising characteristics that make them suboptimal antimicrobials when used alone, and additional caveats are required for AST breakpoint interpretive criteria and stewardship programs. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809955/ http://dx.doi.org/10.1093/ofid/ofz360.1398 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Pogue, Jason M Jones, Ronald N Bradley, John S Andes, David Bhavnani, Sujata M Dudley, Michael Flamm, Robert K Rodvold, Keith A Ambrose, Paul G 1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) |
title | 1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) |
title_full | 1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) |
title_fullStr | 1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) |
title_full_unstemmed | 1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) |
title_short | 1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) |
title_sort | 1534. polymyxin antimicrobial susceptibility (ast) testing and breakpoints for p. aeruginosa, a. baumannii, and enterobacteriaceae: recommendations from the united states committee on antimicrobial susceptibility testing (uscast) |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809955/ http://dx.doi.org/10.1093/ofid/ofz360.1398 |
work_keys_str_mv | AT poguejasonm 1534polymyxinantimicrobialsusceptibilityasttestingandbreakpointsforpaeruginosaabaumanniiandenterobacteriaceaerecommendationsfromtheunitedstatescommitteeonantimicrobialsusceptibilitytestinguscast AT jonesronaldn 1534polymyxinantimicrobialsusceptibilityasttestingandbreakpointsforpaeruginosaabaumanniiandenterobacteriaceaerecommendationsfromtheunitedstatescommitteeonantimicrobialsusceptibilitytestinguscast AT bradleyjohns 1534polymyxinantimicrobialsusceptibilityasttestingandbreakpointsforpaeruginosaabaumanniiandenterobacteriaceaerecommendationsfromtheunitedstatescommitteeonantimicrobialsusceptibilitytestinguscast AT andesdavid 1534polymyxinantimicrobialsusceptibilityasttestingandbreakpointsforpaeruginosaabaumanniiandenterobacteriaceaerecommendationsfromtheunitedstatescommitteeonantimicrobialsusceptibilitytestinguscast AT bhavnanisujatam 1534polymyxinantimicrobialsusceptibilityasttestingandbreakpointsforpaeruginosaabaumanniiandenterobacteriaceaerecommendationsfromtheunitedstatescommitteeonantimicrobialsusceptibilitytestinguscast AT dudleymichael 1534polymyxinantimicrobialsusceptibilityasttestingandbreakpointsforpaeruginosaabaumanniiandenterobacteriaceaerecommendationsfromtheunitedstatescommitteeonantimicrobialsusceptibilitytestinguscast AT flammrobertk 1534polymyxinantimicrobialsusceptibilityasttestingandbreakpointsforpaeruginosaabaumanniiandenterobacteriaceaerecommendationsfromtheunitedstatescommitteeonantimicrobialsusceptibilitytestinguscast AT rodvoldkeitha 1534polymyxinantimicrobialsusceptibilityasttestingandbreakpointsforpaeruginosaabaumanniiandenterobacteriaceaerecommendationsfromtheunitedstatescommitteeonantimicrobialsusceptibilitytestinguscast AT ambrosepaulg 1534polymyxinantimicrobialsusceptibilityasttestingandbreakpointsforpaeruginosaabaumanniiandenterobacteriaceaerecommendationsfromtheunitedstatescommitteeonantimicrobialsusceptibilitytestinguscast |